Evidence map›Paper›PMID 35530292›Full record

ArticleAmerican journal of cancer research2022

The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan.

Shih-Hung Yang, Nai-Jung Chiang, Sz-Chi Chiu, Wen-Chi Chou, Li-Yuan Bai, Chung-Pin Li, Yung-Yeh Su, Tai-Jan Chiu, Shih-Chang Chuang, Cheng-Ming Peng and 7 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Shih-Hung YangDepartment of Oncology, National Taiwan University Hospital Taipei, Taiwan.
Nai-Jung ChiangDepartment of Oncology, Taipei Veterans General Hospital Taipei, Taiwan.
Sz-Chi ChiuPharmaEngine, Inc. Taipei, Taiwan.
Wen-Chi ChouDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou and College of Medicine, Chang Gung University Taoyuan, Taiwan.
Li-Yuan BaiDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, and China Medical University Taichung, Taiwan.
Chung-Pin LiSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University Taipei, Taiwan.
Yung-Yeh SuNational Institute of Cancer Research, National Health Research Institutes Tainan, Taiwan.
Tai-Jan ChiuDivision of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital Kaohsiung, Taiwan.
Shih-Chang ChuangDivision of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital Kaohsiung, Taiwan.
Cheng-Ming PengDepartment of General Surgery and da Vinci Minimally Invasive Surgery Center, Chung Shan Medical University Hospital Taichung, Taiwan.
De-Chuan ChanDivision of General Surgery, Department of Surgery, Tri-Service General Hospital Taipei, Taiwan.
Jen-Shi ChenDepartment of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou and College of Medicine, Chang Gung University Taoyuan, Taiwan.
Chia-Jui YenDepartment of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan, Taiwan.
Yen-Yang ChenDivision of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital Kaohsiung, Taiwan.
Chang-Fang ChiuDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, and China Medical University Taichung, Taiwan.
Li-Tzong ChenNational Institute of Cancer Research, National Health Research Institutes Tainan, Taiwan.
Yan-Shen ShanDivision of General Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan, Taiwan.
National Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (NalFL) comprises the current standard for gemcitabine-failed metastatic pancreatic ductal adenocarcinoma (PDAC). As liposomes generally accumulate in the spleen, we evaluated the impact of spleen volume on prognosis. We enrolled patients with metastatic PDAC who failed gemcitabine-based therapy and were initiated on NalFL between August 2018 and November 2020. The spleen volume before NalFL administration was evaluated. They were stratified into dose subgroups (i.e. low, < 48 mg/m

Indexed as

doseNanoliposomal irinotecanpancreatic cancerspleen

Identifiers

PMID35530292
PMCPMC9077076
OpenAlexW4285741446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.